OSE Immunotherapeutics SA stock analysis
OSE Immunotherapeutics SA (0RAD) Share Price & Analysis
0RAD Stock Chart & Stats
- Day’s Range
- EUR 1.62 - EUR 1.65
- 52-Week Range
- EUR 1.62 - EUR 5.88
- Previous Close
- EUR 1.69
- Volume
- N/A
- Average Volume (3M)
- 3,254
- Market Cap
- EUR 38.40M
- Enterprise Value
- EUR 128.21M
- Total Cash (Recent Filing)
- EUR 22.65M
- Total Debt (Recent Filing)
- EUR 35.38M
- Price to Earnings (P/E)
- ―
- Beta
- 1.93
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Immunotherapy Focus
A focused presence in oncology and immune-inflammatory diseases gives OSE a coherent therapeutic identity and concentrates resources on areas where immune-system modulation is clinically relevant. This specialization can support deeper expertise and clearer development priorities over the coming quarters.
Multiple Development Platforms
The company is advancing more than one immunotherapy modality across preclinical and clinical stages, creating several potential routes to future value creation. A diversified development portfolio can reduce reliance on a single scientific approach, although outcomes remain dependent on successful advancement.
Improved Leverage Versus 2023
Although current leverage remains meaningful, improvement from the more leveraged 2023 position indicates some progress in balance-sheet structure. This provides a more favorable starting point for managing development spending and future financing needs than the earlier capital position.
Bears Say
Revenue Collapse And Heavy Losses
The sharp contraction in revenue and large 2025 net loss show that recent financial performance is highly unstable rather than steadily scaling. A very small revenue base limits internally generated funding, while continuing losses could weaken the company’s ability to sustain development without additional capital.
Significant Cash Burn
The reversal from strong positive cash generation to substantial operating and free-cash-flow burn materially increases funding dependency. Persistent cash outflows would reduce financial flexibility, potentially forcing OSE to seek financing or adjust development priorities while advancing its pipeline.
Leverage And Equity Erosion
Debt exceeding equity leaves the company with limited balance-sheet cushion relative to its obligations, and the decline in equity shows that losses are eroding capital. If weak profitability persists, leverage may constrain investment capacity and increase the consequences of future funding requirements.
OSE Immunotherapeutics SA News
0RAD FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
What is OSE Immunotherapeutics SA’s market cap?
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
How were OSE Immunotherapeutics SA’s earnings last quarter?
Is OSE Immunotherapeutics SA overvalued?
Does OSE Immunotherapeutics SA pay dividends?
What is OSE Immunotherapeutics SA’s EPS estimate?
How many shares outstanding does OSE Immunotherapeutics SA have?
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc Le Bozec
- Employees
- 64
- Website
- www.ose-immuno.com
- Address
- 22, boulevard Benoni Goullin, Nantes, PL, 44200, FR
OSE Immunotherapeutics SA (0RAD) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |










